Clincosm LogoSign in Get a demo

Recurrent Endometrial Carcinoma

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer, Endometrioid Tumor, Cancer Trial in Oklahoma City (nab-sirolimus)

Not yet recruiting
  • Endometrial Cancer
  • +5 more
  • Oklahoma City, Oklahoma
    University Oklahoma Stephenson Cancer Center
Aug 16, 2023

Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • +8 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +7 more
  • (no location specified)
Jul 15, 2023

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023

Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen

Not yet recruiting
  • Metastatic Endometrial Carcinoma
  • +7 more
  • Biopsy
  • +5 more
  • (no location specified)
Jan 18, 2023

Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma Trial in Miami (Lenvatinib, Pembrolizumab, Hypofractionated

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma
  • Miami, Florida
    University of Miami
Jan 10, 2023

Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma Trial in Canada, United States

Active, not recruiting
  • Advanced Endometrial Carcinoma
  • +4 more
  • Cabozantinib S-malate
  • Nivolumab
  • Phoenix, Arizona
  • +33 more
Nov 1, 2022

Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Carcinoma
  • Biopsy
  • +5 more
  • (no location specified)
Sep 29, 2022

Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma Trial in

Recruiting
  • Recurrent Endometrial Carcinoma
  • +12 more
  • Houston, Texas
  • +1 more
Sep 22, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma Trial in

Recruiting
  • Endometrial Clear Cell Adenocarcinoma
  • +17 more
  • Birmingham, Alabama
  • +376 more
Aug 24, 2022

Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +24 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 6, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Los Angeles

Recruiting
  • Recurrent Endometrial Carcinoma
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 28, 2021

Trametinib With or Without Uprosertib on Biomarkers in

Completed
  • Recurrent Endometrial Carcinoma
  • Biospecimen Collection
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2020

Recurrent Endometrial Carcinoma Trial in Philadelphia (bevacizumab, laboratory biomarker analysis)

Completed
Has Results
  • Recurrent Endometrial Carcinoma
  • bevacizumab
  • laboratory biomarker analysis
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jul 22, 2019

Recurrent Endometrial Carcinoma Trial in United States (bevacizumab, temsirolimus)

Completed
Has Results
  • Recurrent Endometrial Carcinoma
  • Hartford, Connecticut
  • +40 more
Jul 19, 2019

Recurrent Endometrial Carcinoma Trial in United States (ziv-aflibercept)

Completed
Has Results
  • Recurrent Endometrial Carcinoma
  • ziv-aflibercept
  • Hartford, Connecticut
  • +66 more
Jul 19, 2019

Anxiety Disorder, Depression, Fatigue Trial in Columbus (other, procedure, behavioral)

Completed
  • Anxiety Disorder
  • +19 more
  • questionnaire administration
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Oct 8, 2015

Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma Trial in Kingston

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +9 more
  • Kingston, Ontario, Canada
    National Cancer Institute of Canada Clinical Trials Group
Feb 5, 2015

Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma Trial (drug, device, other)

Withdrawn
  • Atypical Endometrial Hyperplasia
  • +10 more
  • megestrol acetate
  • +3 more
  • (no location specified)
Sep 9, 2014

Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer Trial in

Completed
  • Advanced Adult Primary Liver Cancer
  • +87 more
  • Charlottesville, Virginia
    University of Virginia
Sep 27, 2013

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma Trial in Columbus (trastuzumab, paclitaxel,

Completed
  • Male Breast Cancer
  • +6 more
  • trastuzumab
  • +2 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 3, 2013

Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases Trial in Columbus (recombinant interleukin-12,

Completed
  • Advanced Adult Primary Liver Cancer
  • +126 more
  • recombinant interleukin-12
  • ABI-007/carboplatin/trastuzumab
  • Columbus, Ohio
    Ohio State University Medical Center
Feb 27, 2013

Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma Trial in Philadelphia

Completed
  • Endometrial Adenoacanthoma
  • +5 more
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Jan 23, 2013

Ovarian Carcinoma, Recurrent Endometrial Carcinoma Trial (Tc 99m EC20)

Completed
  • Ovarian Carcinoma
  • Recurrent Endometrial Carcinoma
  • Tc 99m EC20
  • (no location specified)
Sep 17, 2012